COVID-19 pneumonia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png COVID-19 pneumonia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of vitamin D3 (cholecalciferol) as additional treatment for elderly patients with pneumonia or sepsis due to infection https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ Wed, 29 Apr 2026 15:06:23 +0000 https://clinicaltrials.eu/trial/study-of-vitamin-d3-cholecalciferol-as-additional-treatment-for-elderly-patients-with-pneumonia-or-sepsis-due-to-infection/ This clinical trial investigates the effects of high-dose vitamin D3 (cholecalciferol) in elderly patients who are hospitalized with either pneumonia or sepsis. Pneumonia is a lung infection that can be seen on chest x-rays, while sepsis is a serious condition where the body has an extreme response to an infection that can be life-threatening.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

]]> Study on the Safety of Mercaptamine with Standard Therapy for Hospitalized COVID-19 Pneumonia Patients Not Requiring High Oxygen Flows https://clinicaltrials.eu/trial/study-on-the-safety-of-mercaptamine-with-standard-therapy-for-hospitalized-covid-19-pneumonia-patients-not-requiring-high-oxygen-flows/ Wed, 29 Apr 2026 14:22:54 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-mercaptamine-with-standard-therapy-for-hospitalized-covid-19-pneumonia-patients-not-requiring-high-oxygen-flows/ This clinical trial is focused on studying the effects of a medication called cysteamine in patients who have been hospitalized with COVID-19 pneumonia. COVID-19 is a respiratory illness caused by the coronavirus, which can lead to severe lung infections. The trial aims to evaluate the safety of cysteamine when used alongside standard treatments for COVID-19 pneumonia. Cysteamine is being tested to see if it can help improve the condition of patients who do not require high levels of oxygen support.

Participants in the study will receive cysteamine in the form of hard capsules, taken orally. The study will monitor patients over a period of time to observe any side effects and to assess how the medication interacts with the body. The trial will also track the number of days it takes for patients to recover and be discharged from the hospital. The goal is to determine if cysteamine can be a safe and effective addition to the current treatment options for COVID-19 pneumonia.

Throughout the study, various health indicators will be measured, such as blood markers and the presence of the virus in the body. The trial will also look at how cysteamine affects the expression of certain genes related to the immune response. By the end of the study, researchers hope to gather valuable information on the potential benefits of cysteamine for patients with COVID-19 pneumonia.

]]>